Data for (Study ST002127)

(Analysis AN003480)

Values for each metabolite have been scaled by dividing by the mean across all factors

Run Hierarchial cluster analysis on this study | Run Heatmap cluster analysis on this study

MetaboliteF1F2F3F4F5F6F7F8
[13C, 15N]Alanine, 2TBDMS 0.2258 2.2582 0.6190 1.0301 0.2223 2.2229 0.5118 0.9099
[13C, 15N]Aspartic acid, 3TBDMS 0.1882 1.8818 0.7980 1.2083 0.1884 1.8841 0.7142 1.1371
[13C, 15N]Glutamic acid, 3TBDMS 0.2029 2.0290 0.7491 1.2963 0.1997 1.9974 0.5679 0.9577
[13C, 15N]Glycine, 2TBDMS 0.0166 1.7343 0.8173 1.2894 0.0177 1.7957 0.9502 1.3789
[13C, 15N]Histidine, 3TBDMS 0.2254 2.2535 0.6395 1.2350 0.1995 1.9954 0.4734 0.9782
[13C, 15N]Isoleucine, 2TBDMS 0.1741 1.7409 0.7477 1.2443 0.1973 1.9730 0.6478 1.2748
[13C, 15N]Leucine, 2TBDMS 0.2130 2.1304 0.6359 1.3315 0.1999 1.9993 0.4779 1.0120
[13C, 15N]Lysine, 3TBDMS 0.1935 1.9354 0.7972 1.1036 0.2037 2.0367 0.6318 1.0981
[13C, 15N]Methionine, 2TBDMS 0.2014 2.0145 0.6763 1.1388 0.2042 2.0420 0.5795 1.1433
[13C, 15N]Phenylalanine, 2TBDMS 0.2057 2.0572 0.9306 1.0844 0.1846 1.8463 0.7085 0.9827
[13C, 15N]Proline, 2TBDMS 0.2299 2.2986 0.6122 1.1152 0.2172 2.1718 0.4016 0.9535
[13C, 15N]Serine, 3TBDMS 0.1951 1.9506 0.5683 1.2983 0.2134 2.1337 0.4896 1.1510
[13C, 15N]Threonine, 3TBDMS 0.2096 2.0959 0.8430 1.2348 0.1843 1.8431 0.6575 0.9319
[13C, 15N]Tyrosine, 3TBDMS 0.2170 2.1695 0.7144 1.1055 0.2049 2.0486 0.5566 0.9837
[13C, 15N]Valine, 2TBDMS 0.2011 2.0111 0.7465 1.1922 0.2026 2.0265 0.5692 1.0507
[13C]Alpha_Ketoglutarate NA 5.5271 0.1030 0.0775 NA 0.0601 0.1403 0.0920
[13C]Citrate NA 0.5968 1.1696 0.9819 NA 0.7089 1.3756 1.1673
[13C]Fumatate NA 0.6359 1.2951 0.9946 NA 0.5633 1.4051 1.1060
[13C]Malate NA 0.6846 1.0993 0.9426 NA 0.8912 1.2878 1.0944
[13C]Succinate NA 0.6834 1.2342 0.9761 NA 0.6216 1.3814 1.1033
Run Hierarchial cluster analysis on this study | Run Heatmap cluster analysis on this study

Factors:

F1Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:Ctrl, [13C, 15N] AAs were incorporated for 1 h | Batch:1e | Note:[13C, 15N]AAs were used for AA uptake (FigS6.J)
F2Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:Ctrl, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 0 h | Batch:1e | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L).
F3Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:Ctrl, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 12 h | Batch:1e | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L).
F4Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:Ctrl, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 6 h | Batch:1e | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L).
F5Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:NR 1 week, [13C, 15N] AAs were incorporated for 1 h | Batch:1e | Note:[13C, 15N]AAs were used for AA uptake (FigS6.J)
F6Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:NR 1 week, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 0 h | Batch:1e | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L).
F7Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:NR 1 week, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 12 h | Batch:1e | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L).
F8Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:NR 1 week, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 6 h | Batch:1e | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L).
  logo